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ABSTRACT
Novel agents have increased survival of multiple myeloma (MM) patients, 
however high-risk and relapsed/refractory patients remain challenging to treat and 
their outcome is poor. To identify novel therapies and aid treatment selection for 
MM, we assessed the ex vivo sensitivity of 50 MM patient samples to 308 approved 
and investigational drugs. With the results we i) classified patients based on their ex 
vivo drug response profile; ii) identified and matched potential drug candidates to 
recurrent cytogenetic alterations; and iii) correlated ex vivo drug sensitivity to patient 
outcome. Based on their drug sensitivity profiles, MM patients were stratified into four 
distinct subgroups with varied survival outcomes. Patients with progressive disease 
and poor survival clustered in a drug response group exhibiting high sensitivity to 
signal transduction inhibitors. Del(17p) positive samples were resistant to most 
drugs tested with the exception of histone deacetylase and BCL2 inhibitors. Samples 
positive for t(4;14) were highly sensitive to immunomodulatory drugs, proteasome 
inhibitors and several targeted drugs. Three patients treated based on the ex vivo 
results showed good response to the selected treatments. Our results demonstrate 
that ex vivo drug testing may potentially be applied to optimize treatment selection 
and achieve therapeutic benefit for relapsed/refractory MM.
INTRODUCTION
Immunomodulatory drugs and proteasome inhibitors 
combined with alkylating agents and steroids have 
improved the outcome of MM patients [1]. While some 
patients experience long remission, prognosis is still poor 
for high-risk patients. Heterogeneity in treatment response 
may be influenced by several patient or disease related 
features such as frailty, age, comorbidity, clinical stage and 
the presence of one or more cytogenetic abnormalities [2]. 
Patients may exhibit both de novo or acquired resistance to 
current therapies by mechanisms (i.e. clonal heterogeneity 
and evolution) that are still poorly understood [3]. Prior 
information on responses to approved myeloma and other 
oncology drugs remains crucial to determine the timing 
and sequence of treatments. With the recent exception of 
venetoclax in BCL-2 driven t(11;14) MM [4], genomically 
guided treatments have not been successful in MM. Other 
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targeted agents such as mTOR and HDAC inhibitors have 
been clinically investigated, however, these were not 
biomarker driven studies and thus not targeted to patients 
likely to respond [5–10]. A real time and viable means of 
assessing drug response using the patient’s own malignant 
cells could accelerate the design of individualized 
treatment strategies and improve outcome.
The myeloma genome contains complex cytogenetic 
alterations that affect both the number and structure of 
chromosomes [11]. Recurrent cytogenetic alterations 
are well recognized as biomarkers defining treatment 
outcome and prognosis. Based on the presence or absence 
of these alterations myeloma has been stratified into high-
risk (HR), standard-risk (SR) and low-risk (LR) groups, 
with del(17p) and in general t(4;14) indicating the worst 
prognosis among the cytogenetic aberrations [12–14]. New 
drugs and therapeutic innovations are urgently needed 
for HR patients who comprise 20% of the myeloma 
population and have a median overall survival of only two 
years. Furthermore, patients who are refractory to both 
bortezomib and lenalidomide have very poor outcome 
with median survival of only nine months [15]. Several 
efforts have elucidated the genomic landscape in myeloma 
[16–22], albeit systematic analysis linking cytogenetic 
alterations to drug response is lacking.
Increasing genomic complexity during disease 
progression leads to the activation of multiple signaling 
pathways that are known to contribute to treatment 
resistance, which can potentially be targeted using signal 
transduction inhibitors in combination with approved 
drugs. However, it is extremely important to identify 
the responding patients in advance to apply those drugs 
to maximize benefit. Here, we describe ex vivo drug 
sensitivity and resistance profiling of 50 MM patient 
samples to 308 drugs and use the overall drug response 
profile to classify patients. We compared the responses 
to the patient cytogenetics to identify potential drug 
candidates for each karyotype and identify novel treatment 
strategies for relapsed/refractory (RR) MM. Results were 
used to tailor treatment for three patients. Our studies 
indicate that an individualized approach by functional, 
ex vivo drug testing may be effectively applied to MM to 
provide additional information to guide treatment selection 
and potentially improve therapeutic benefit.
RESULTS
Myeloma patients can be stratified based on 
distinct drug sensitivity profiles
To assess drug efficacy and compare the drug 
response data across patient samples we used a quantitative 
drug sensitivity score (DSS). DSS is a modified form of 
the area under the curve (AUC) calculation that integrates 
multiple dose response parameters for each drug, while a 
selective drug sensitivity score (sDSS) was calculated by 
taking into account the sensitivity of healthy BM control 
samples (n = 8) to the drugs and subtracting the mean 
DSS of the controls from the DSS of the tumor sample 
[23, 24]. Unsupervised hierarchical clustering of the DSS 
and sDSS for each patient identified four distinct patient 
groups (I-IV) based on their sensitivity to 308 drugs 
(summary of molecules of interest and sDSS of samples 
in Figure 1A and all results shown in Supplementary 
Figures 1 and 2). Conventional chemotherapeutics and 
proteasome inhibitors were relatively non-selective when 
comparing the responses to these drugs between myeloma 
patient and healthy donor cells. However, the patient 
samples showed varied responses to targeted agents 
including many signal transduction inhibitors across the 
different chemosensitivity groups. Samples in group I 
(n = 16) showed selective sensitivity to several signal 
transduction inhibitors including those targeting IGF1R-
PI3K-mTOR, HDAC, MEK, CDK and HSP90 (Figure 
1B and Supplementary Figure 4A). Although group II 
samples (n = 13) responded to many of the same drugs, 
the sensitivities were more moderate, in particular to 
MEK, HDAC and HSP90 inhibitors. In addition, group II 
samples lacked sensitivity to rapalogs. In contrast, group 
III samples (n = 18) were relatively insensitive to many 
targeted therapies and exhibited diminished response 
to most drugs compared to healthy controls. The most 
striking response was observed for group IV (n = 3). 
Although the number of samples comprising this group 
was small, the samples were distinctively resistant to 
almost all drugs tested with the exception of bryostatin1 
and the pan-BCL2 inhibitor navitoclax (Figure 1A 
and 1B). In addition, BCL2 inhibitors were active across 
all four chemosensitivity groups (Figure 1A).
Signal transduction inhibitors selectively target 
multiple myeloma cells
To determine if the drug responses were specific 
for CD138+ cells, we tested separately CD138+ cells 
and the remaining BM-MNCs (CD138-) using samples 
from nine patients. Supplementary Table 1 CD138- cells 
exhibited little sensitivity to signal transduction inhibitors 
targeting PI3K-AKT-mTOR, MAPK, and IGF1R, HSP90 
and BCL2 family members, with responses similar to 
that observed in BM cells from healthy individuals. In 
contrast, MM derived CD138+ cells were insensitive to 
nucleoside analogues including clofarabine, cladribine 
and gemcitabine, while CD138- cells were sensitive 
(Figure 1C). The drug sensitivity pattern of MM CD138+ 
cells suggests dependence on specific signaling pathways 
known to be pathogenic in MM and which can potentially 
be therapeutically exploited.
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Figure 1: Ex vivo drug sensitivity profiling results in stratification of MM patients in four chemosensitivity subgroups. 
(A) Summary view of clustering analysis of myeloma patients based on their overall ex vivo drug sensitivity. The distinct drug response 
patterns results in four taxonomic groups. Columns represent samples and rows represent drugs. The data summarize the selective drug 
sensitivity scores (sDSS) of the samples to the drugs. Detailed heatmaps are shown in Supplementary Figures 1 and 2. Bootstrap analysis 
to show stability of clustering is shown in Supplementary Figure 3. (B) Ex vivo responses (DSS) by group to a selection of approved and 
investigational drugs. Graphs comparing IC50 for the same drugs are presented in Supplementary Figure 4B. (C) Comparison of mean 
ex vivo responses (DSS) to all tested drugs in paired CD138+ and CD138- cells for 9 individual MM patients. Red indicates drugs that 
show better effect to CD138+ cells. Blue indicates drugs that target CD138- cells. Correlation plots for individual samples are shown in 
Supplementary Figure 5.
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Acquired sensitivity to targeted therapies 
predicts poor survival
To assess the value of the drug sensitivity results 
in predicting patient outcome, we compared time to next 
therapy (TTNT) among the four different chemosensitivity 
groups. While most of the samples analyzed came from 
relapsed/refractory patients with expected poor outcome, 
TTNT differed between the four groups (Figure 2A). 
Interestingly, patients comprising the most sensitive group 
to signal transduction inhibitors (Group I) had progressive 
disease with very short TTNT and overall survival (Figure 
2A and 2B) with a hazard ratio of 4.66 (CI95% 1.71–
12.77). Patients comprising groups II and III exhibited 
similar TTNT, and although group IV patients were too 
few to evaluate, these patients showed short treatment 
response followed by progression.
Correlation with cytogenetic alterations reveals 
novel treatment options for high-risk myeloma 
patients
Myeloma cells contain numerous and complex 
genetic alterations with several karyotypes of prognostic 
importance including those for HR patients such as 
del(17p), t(4;14), t(14;16) and 1q gain. We investigated 
if there was correlation between drug response profiles 
and karyotypes. Samples from patients with t(4;14) 
predominantly clustered in group II (n = 8/13), but 
were also present in group III (n = 3/18) and group I 
(n = 2/16) (Figure 3A), while samples from patients with 
del(17p) were present in all groups, but predominant in 
the more resistant groups III (n = 4/18) and IV (n = 2/3) 
(Figure 3A). Samples from two patients with both del(17p) 
and t(4;14) clustered in groups I and II.
Del(17p) patient samples tended to be very resistant 
with some exceptions. For example, del(17p) along with 
other HR patient samples exhibited good sensitivity 
to panobinostat (Figure 3B).  The del(17p) cells were 
also sensitive to pan-BCL2 inhibitor navitoclax (Figure 
3B and 3C) and modestly to specific BCL2 inhibitor 
venetoclax, although samples from patients with other 
karyotypes also showed similar sensitivity (Figure 3C). The 
highest sensitivity to venetoclax was observed in samples 
from patients with t(11;14) and t(14;16) (Supplementary 
Figure 6A). The del(17p) samples were sensitive to several 
other drugs, but these drugs were less selective and showed 
similar activity against healthy BM cells (Figure 3B and 3C).
In contrast, t(4;14) cells were less sensitive to 
navitoclax, but were highly sensitive to pomalidomide 
(Figure 3B and 3C). The t(4;14) samples were also 
sensitive to proteasome inhibitors, although the activity of 
these drugs tended to be less selective in the assay. Other 
drugs with activity against t(4;14) samples were IGF1R 
(BMS-754807 and linsitinib) and dual PI3K-mTOR 
inhibitors (GSK2126458, PF-04691502), suggesting 
potential activity of these signaling molecules in t(4;14) 
cells (Supplementary Figure 6A). In addition, t(4;14) 
samples were sensitive to GSK-J4, an inhibitor of the 
histone lysine demethylase JMJD3/KDM6B (Figure 3C). 
Interestingly, FGFR inhibitors such as dovitinib and 
NVP-BGJ398 lacked efficacy towards t(4;14) cells 
although FGFR3 was highly expressed in these samples 
(Supplementary Figure 7).
Ex vivo-in vivo correlation of drug sensitivity
For three patients with advanced stage disease, 
treatment was decided based on the drug testing results. 
Two t(4;14) positive relapsed patients showing extremely 
good ex vivo sensitivity to pomalidomide (Figure 4A) 
were treated with a combination of pomalidomide 
and dexamethasone. Pomalidomide was used at 4 mg/
day on days 1-21 and dexamethasone 40 mg weekly 
of each 28-day cycle. The combination resulted in 
minimal response for 32 weeks with eight cycles for 
the first patient and partial response for 16 weeks with 
four cycles for the second patient (Figure 4B and 4C). 
Oral cyclophosphamide 450 mg weekly was added to 
the latter patient resulting in sustained partial response 
after six cycles, 24 weeks. Lack of ex vivo sensitivity to 
dexamethasone (Supplementary Figure 8) suggested that 
pomalidomide and not dexamethasone had a direct anti-
tumor effect in vivo.
For a t(11;14) patient, drug testing analysis at the 
time of relapse showed exceptional sensitivity to rapalogs 
(temsirolimus, everolimus and ridaforolimus) (Figure 4D). 
Prior to testing, the patient had previously received three 
cycles of bortezomib, lenalidomide and dexamethasone 
followed by a single autologous stem cell transplant and 
lenalidomide maintenance resulting in stringent complete 
remission for 11 months. Ex vivo drug testing showed 
that the cells were sensitive to bortezomib, modestly 
sensitive to immunomodulatory drugs, but insensitive to 
dexamethasone (Supplementary Figure 9).  Based on a 
phase II study, the patient was treated with a combination 
of bortezomib and temsirolimus (bortezomib 1.6 mg/m2 
on days 1, 8, 15 and 22 and temsirolimus 25 mg on days 
1, 8, 15, 22, 29 for 35-day cycles) [6, 25]. The patient 
experienced a dramatic response with rapid reduction of 
serum free light chain lambda from 1550 mg/L to 343 
mg/L in two weeks. Progression free survival of 84 days 
was achieved before the second progression (Figure 4E). 
At this point another BM sample was taken and drug 
sensitivity assessed. An overall decrease in drug response 
was seen with loss of sensitivity to temsirolimus compared 
to the previous sample (Figure 4F). Exome sequence 
analysis of the samples showed small changes in the clonal 
composition between pre- and post-temsirolimus treatment 
(Figure 4G). The Ras pathway, which is upstream of 
mTOR, was likely activated by mutations to NRAS 
and NF1, with the NRAS mutation and a REL mutation 
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Figure 2: Drug sensitivity stratification predicts disease progression and overall survival. (A) Time to next treatment 
(TTNT) for relapsed patients (n = 27) and patients at diagnosis who had relapsed (n = 1) from the four different chemosensitivity groups. 
Colored bar sections represent the different lines of treatment and black arrowheads indicate sampling time for ex vivo drug testing. (B) 
Kaplan-Meier graph showing significant differences in overall survival of the patients comprising the four chemosensitivity groups.
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Figure 3: Cytogenetic markers of the chemosensitivity groups and top scoring drugs for high-risk patients. (A) 
Cytogenetic markers for the drug-tested patients in relation to the chemosensitivity groups. Samples from patients with del(17p) were 
predominantly in groups III and IV, while the majority of t(4;14) patient samples were in group II. (B) Ex vivo drug responses to standard 
of care and recently approved drugs as well as the investigational drug navitoclax and histone demethylase inhibitor GSK-J4 subdivided 
by specific cytogenetic alterations (del(17p), n = 10; t(4;14), n = 13; t(11;14), n = 7; +1q, n = 24; t(14;16), n = 3; del14q32, n = 7). Graphs 
using IC50 for the same drugs are presented in Supplementary Figure 6B. (C) Top scoring selective inhibitors for del(17p) and t(4;14) 
patients (top bar plots), and the most active inhibitors (lower bar plots) with approved drugs indicated in red.
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Figure 4: Ex vivo – in vivo correlation of drug response. (A) The waterfall plot ranks the patients based on ex vivo sensitivity to 
pomalidomide, with two patients treated with pomalidomide based on the drug sensitivity results highlighted in red. (B and C) Responses 
to pomalidomide and earlier lines of treatment based on serum M component level for the two patients R_MM_899 and R_MM_1862. 
(D) The most selective drugs for the first sample from patient R_MM_2757_1 tested in the ex vivo assay. Top scoring selective drugs 
included rapalogs temsirolimus, everolimus and ridaforolimus highlighted in red. (E) Response of the R_MM_2757 patient to different 
lines of treatment including the combination of temsirolimus and bortezomib as measured by serum Iglcλ level. (F) Ex vivo sensitivity of 
CD138+ cells from the R_MM_2757 patient pre- (blue line) and post-temsirolimus/bortezomib treatment (red line) with a shift in dose 
response curve indicating acquired resistance. (G) Cancer cell fractions for  (CCF) of somatic alterations to genes of interest in the pre- 
(R_MM_2757_1) and post-temsirolimus (R_MM_2757_2) treatment samples from patient R_MM_2757. 
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enriched in the post-temsirolimus treatment sample. In 
addition, a mutation to DNA-Damage-Inducible Transcript 
4 (DDIT4), a repressor of mTORC1, was also detected 
in both samples [26–28]. These events collectively could 
render the cells dependent on mTOR signaling as indicated 
by the sensitivity to rapalogs, while mutations to NRAS 
and NF1 may have also contributed to the sensitivity to 
MEK inhibitors (e.g. pimasertib, TAK-733, refametinib, 
trametinib, selumetinib). 
DISCUSSION
Considering both genetics and clinical outcome, 
multiple myeloma presents extreme inter- and intra-
individual heterogeneity [21] resulting in varied treatment 
response and highlighting the importance of defining 
patient populations prior to treatment with targeted 
therapies. In this study we showed that this variation is 
also observed through comprehensive drug sensitivity 
profiling and patients could be classified into different 
chemosensitive groups based on their ex vivo drug 
response profiles. Surprisingly, correlating the groups 
to patient outcome showed that patients comprising the 
most highly sensitive group (group I) had the shortest 
survival. As inferred from susceptibility to numerous 
signal transduction inhibitors, the activation of multiple 
signaling pathways in the malignant cells may drive the 
disease of these patients and potentially be the cause of 
relapse and acquired resistance to approved therapies. 
Noticeably, many group I samples were from standard-
risk patients at relapse and end stage disease. While the 
samples exhibited sensitivity to many current therapies, 
multiple escape routes could circumvent blockade on 
growth. These patients could potentially benefit from 
treatment strategies based on signal transduction inhibitors 
combined with other standard therapies.
Among standard of care drugs, there was 
considerable variation in response to glucocorticoids. 
Dexamethasone, methylprednisolone and prednisolone 
showed similar patterns in efficacy with clearly responsive 
and non-responsive samples. Further analysis of mutation 
and gene expression profiles is needed to identify 
potential indicators of response, such as mutations to 
the glucocorticoid receptor or specific gene expression 
signatures [29, 30]. Emerging studies are providing a 
much better understanding of the impact of therapy on 
the clonal architecture and evolution of the disease [31, 
32]. Although exome sequence analysis of samples taken 
before and after bortezomib/temsirolimus treatment of one 
patient did not reveal any newly acquired mutations, the 
clonal cell fractions differed between samples indicating 
that even targeted treatments can have an impact on 
clonal architecture. Nevertheless, knowledge of the drug 
sensitivity landscape by ex vivo testing before treatment 
can potentially be exploited for patients who are more 
refractory to currently used therapies and may benefit 
from tailored treatment, while molecular profiling will be 
helpful to understand changes induced by treatment and 
identify indicators of response.
By correlating standard cytogenetic markers with 
drug response profiles, we evaluated if any genetically 
driven treatment options were available, particularly for 
high-risk patients. Cells with t(4;14) were sensitive to 
proteasome inhibitors and immunomodulatory drugs. This 
is supported by findings from a clinical trial suggesting 
that high-risk patients with t(4;14) are likely to benefit 
from receiving these drugs as frontline treatment [33]. The 
t(4;14) leads to overexpression of FGFR3 and MMSET 
[34]. Although we observed enhanced expression of 
FGFR3 in the t(4;14) samples, the cells were not sensitive 
to FGFR inhibitors (e.g. dovitinib, NVP-BGJ398). 
Efficacy of FGFR3 inhibitors has been explored in MM 
and other indications with FGFR1-3 amplifications or 
somatic aberrations [35–37]. However, single agent 
activity is modest and often independent of FGFR 
status. MMSET encodes the histone methyltransferase 
NSD2 [38]. Deregulation of MMSET is associated with 
a global increase in dimethylation of lysine 36 on histone 
H3 (H3K36me2) and simultaneous decrease in lysine 
27 trimethylation on histone H3 (H3K27me3), which 
is a repressive histone modification [29, 30]. We found 
that t(4;14) cells were sensitive to GSK-J4, an inhibitor 
of the histone demethylase JMJD3/KDM6B, which has 
H3K27me3 as a substrate. For del(17p) samples, the drug 
response profiles correlated to the clinical scenario with 
the cells resistant to most drugs tested. There were few 
drugs that showed selective activity towards del(17p) 
cells. However, the cells tended to be more sensitive 
to panobinostat and relapsed del(17p) patients could 
potentially benefit from this drug. The del(17p) cells were 
also sensitive to the BCL2/BCL-xL inhibitor navitoclax, 
and modestly sensitive to specific BCL2 inhibitor 
venetoclax, suggesting that anti-apoptotic factors such 
as BCL-xL may be important for del(17p) cell survival. 
Our results with BCL2 inhibitors together with earlier 
studies [39–41] further emphasize the need for clinical 
investigations with these drugs.
Comparison of drug responses between MM 
CD138+, MM CD138- and healthy BM cells allowed 
us to distinguish between malignant and non-malignant 
responses, and identify drugs with maximum efficacy 
against MM plasma cells and minimal activity towards 
healthy cell populations. Our results demonstrate that 
sensitivity to several signal transduction inhibitors could 
be observed in the MM plasma cell fraction, whereas 
the response in the non-plasma cell fraction was similar 
to that of healthy individuals. These results emphasize 
that molecular alterations present in malignant plasma 
cells may be selectively exploited by targeted therapies 
thereby minimizing treatment related toxicities to other 
cell populations. Although the platform was useful at 
determining drug responses on the tested cell population, 
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it will be important to develop the assay further to take 
into account the effects of the microenvironment on drug 
response. While the supportive culture medium was 
from a bone marrow stromal cell line, the assay could 
not account for cell adhesion mediated drug resistance 
or the impact of hypoxia on drug response. These could 
be assessed using for example cell co-cultures [42] and 
hypoxia chambers. Furthermore, it will be important to 
ascertain indirect tumor cytotoxicity of the drugs through 
stimulation of other immune cells by immunomodulatory 
drugs. Nonetheless, the current assay provides a means to 
quickly assess the impact of hundreds of drugs at several 
concentrations on individual patient samples.
Guiding treatment decisions based on personalized 
drug sensitivity testing is compelling and has not been 
widely investigated. We observed exceptional sensitivity to 
rapalogs for one patient and to pomalidomide for two other 
patients in the ex vivo assay, accompanied by very clear 
in vivo response. Our results show that comprehensive, 
functional, drug sensitivity assessment applied to MM 
patients provides information that can be used to understand 
variability in drug response and to classify patients based 
on their chemosensitivity profile. Importantly, we were 
able to identify candidate drugs that may be effective for 
treating HR and RRMM patients and the assay provided 
informative results to guide treatment selection. By using 
a panel of signal transduction inhibitors, we were able 
to identify active pathways in the MM cells targetable 
by these drugs and which can be further investigated for 
drug development. As more drugs are approved for MM, 
determining the best treatment and timing for each patient 
becomes more challenging. Ex vivo testing may therefore 
be clinically useful for therapy guidance.
MATERIALS AND METHODS
Patients and samples
The ethics committees of the participating hospitals 
approved the study with patient and healthy donor samples 
obtained following informed consent in compliance with 
the Declaration of Helsinki. A total of 58 bone marrow 
(BM) aspirates were collected from 16 diagnostic 
and 27 relapse patients and 8 healthy donors. Patient 
characteristics are detailed in Supplementary Table 2. 
No exclusion criteria were applied to the patients and the 
samples were collected prospectively. Data collection 
was continued at successive relapses to follow disease 
progression.
Cytogenetics
Plasma cells were selected by immunomagnetic 
bead enrichment of CD138+ cells (Human Whole 
Blood CD138 Microbeads Column kit, Miltenyi Biotec, 
Bergisch Gladbach, Germany). Selected cells (n ≥ 100) 
were used for interphase fluorescence in situ hybridization 
(FISH) following the guidelines of the European 
Myeloma Network 2012 [43]. FISH probes are listed in 
Supplementary Table 3.
Drug sensitivity and resistance testing
CD138+ cells were enriched using the EasySep™ 
Human CD138 Positive Selection kit (StemCell 
Technologies, Grenoble, France) from the mononuclear 
cell fraction of BM aspirates following gradient separation 
(Ficoll-Paque PREMIUM; GE Healthcare, Little Chalfont, 
Buckinghamshire, UK). Drug sensitivity and resistance 
testing (DSRT) was performed based on methods 
described previously [23]. CD138+ cells derived from 
myeloma patients were tested against 308 compounds at 
5 concentrations in 10-fold dilutions covering a 10,000-
fold concentration range (1–10,000 nM). The drug 
panel included approved oncology drugs (n = 141) and 
investigational compounds (n = 167) targeting multiple 
signaling networks and molecular targets (Supplementary 
Table 4). In brief, 5µl of cell culture medium comprised 
of RPMI 1640 medium supplemented with 10% fetal 
bovine serum, 2 mM L-glutamine, penicillin (100 U/ml), 
streptomycin (100 µg/ml) and 25% conditioned medium 
from the HS-5 human BM stromal cell line was added 
to 384 well drug plates and shaken for 5 min to dissolve 
the compounds. CD138+ cells were diluted in the culture 
medium and 20µl of the cell suspension containing 5000 
cells was transferred to each well using a MultiDrop 
Combi peristaltic dispenser (Thermo Scientific, Waltham, 
MA, USA). The plates were incubated in a humidified 
environment at 37°C and 5% CO2. Cell viability was 
measured after 72 h using the CellTiter-Glo assay 
(Promega, Madison, WI, USA) with a PHERAstar® 
microplate reader (BMG-Labtech, Offenburg, Germany) 
to measure luminescence. The mean viability of untreated 
cells at day three was 124 ± 10.40%. The data was 
normalized to negative (DMSO only) and positive control 
wells (containing 100 µM benzethonium chloride).
Ex vivo drug sensitivity data analysis
Output from the plate reader was used as input for 
Dotmatics software (Dotmatics Ltd, Bishops Stortford, 
Herts, UK) to generate dose response curves of individual 
drugs. A four parameter (maximum and minimum 
response, slope and IC50) logistic regression was applied 
to fit the dose response curves. Curve fitting parameters 
were further used to quantitate drug responses with a drug 
sensitivity score (DSS) as described previously [24]. DSS 
is a modified form of the area under the curve calculation 
that takes into account all four curve fitting parameters 
of a non linear response model, generating a single 
response metric that was used for downstream analyses. 
Higher DSS corresponds to higher sensitivity. Selective 
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drug sensitivity scores (sDSS) indicating tumor specific 
sensitivity to the drugs were calculated by subtracting the 
mean DSS values obtained by testing BM cells from eight 
healthy individuals from the DSS values of the patient 
samples. To evaluate the relatedness of drug response 
profiles across all myeloma samples, we performed 
unsupervised hierarchical ward linkage clustering using 
Spearman correlation and Euclidean distance measures of 
the drug and sample profiles, respectively. Robustness and 
reproducibility of the identified subgroups/clusters were 
evaluated by resampling (n = 1000) using a bootstrapping 
method with Pvclust R-package [44].
Exome sequencing
Genomic DNA was isolated from a skin biopsy 
and CD138+ cells using the DNeasy Blood & Tissue kit 
or AllPrep DNA/RNA/miRNA Universal kit (Qiagen, 
Hilden, Germany). Exome capture was performed using 
the SureSelect Clinical Research Exome kit or the 
SureSelect Human All Exon V5 kit (Agilent Technologies, 
Santa Clara, CA, USA). Sequencing was performed on 
HiSeq 1500 and 2500 instruments (Illumina, San Diego, 
CA, USA). For the skin germline control 4 × 107 and 
10×107 2×100 bp paired-end reads were sequenced for 
the skin germline control and CD138+ cells, respectively. 
Somatic mutations were identified and annotated as 
described earlier [45]. The cancer cell fraction has been 
calculated by using the variant allele frequency corrected 
by the gene ploidy and the estimated tumor purity. 
Statistical analyses
Statistical analyses were performed using 
GraphPad Prism version 5.0 for Mac OS, (GraphPad 
Software, La Jolla, California, USA) and SPSS version 
23.0 Software (IBM, Endicott, New York, USA). One-
way ANOVA followed by Tukey’s multiple comparisons 
test was performed to test variances among different 
groups in the scatterplots. Univariate survival analysis 
was carried out using the Kaplan-Meier method 
with log-rank test and survival curves presented. 
Multivariate survival analysis was performed with 
the Cox proportional hazard model with DSRT group, 
age, gender, paraprotein subtype, HR cytogenetics and 
clinical treatment sensitivity used as predictors. Variable 
selection was performed with the forward stepwise 
method. Results from multivariate survival analysis 
were presented with hazard ratios and 95% confidence 
intervals. In this study, the statistical significance level 
was a p-value under 0.05.
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